Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Ospedale San Donato |
---|---|
Information provided by: | Ospedale San Donato |
ClinicalTrials.gov Identifier: | NCT00882739 |
The aim of this study is to determine both safety and effectiveness of three different loading dose regimens of clopidogrel in patients with acute myocardial infarction undergoing primary angioplasty.
Condition | Intervention | Phase |
---|---|---|
Acute Myocardial Infarction |
Drug: Clopidogrel 300 mg Drug: Clopidogrel 600 mg Drug: Clopidogrel 900 mg |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Safety and Efficacy of Three Different Loading Doses of Clopidogrel, Administered at First Medical Contact in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. The LOAD & GO Trial |
Estimated Enrollment: | 150 |
Study Start Date: | April 2009 |
Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
no pre-treatment
No pre-treatment at first medical contact - Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
|
Drug: Clopidogrel 300 mg
Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
|
600 mg loading dose: Experimental
600 mg clopidogrel loading dose at first medical contact
|
Drug: Clopidogrel 600 mg
Patients will receive a 600 mg clopidogrel loading dose at first medical contact
|
900 mg loading dose: Experimental
900 mg clopidogrel loading dose at first medical contact
|
Drug: Clopidogrel 900 mg
Patients will receive a 900 mg clopidogrel loading dose at first medical contact
|
This study will enroll STEMI patients, who were planned to undergo PCI, and will randomize them to three different clopidogrel loading dose regimens at first medical contact: no pre-treatment, 600 mg or 900 mg. Platelet activity after administration of clopidogrel will be evaluated by VerifyNow™ P2Y12 point-of-care system. The study is powered to demonstrate significant differences in the primary end point (the rate of TIMI Myocardial Perfusion Grade=3).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
ST-elevation myocardial infarction:
Exclusion Criteria:
Contact: Leonardo Bolognese, MD, FESC | +390575255529 | leonardobolognese@hotmail.com |
Italy, AR | |
Cardiovascular Department, Ospedale S.Donato | Recruiting |
Arezzo, AR, Italy, 52100 | |
Contact: Leonardo Bolognese, MD, FESC leonardobolognese@hotmail.com | |
Principal Investigator: Leonardo Bolognese, MD, FESC | |
Sub-Investigator: Giovanni Falsini, MD | |
Sub-Investigator: Paolo Angioli, MD | |
Sub-Investigator: Kenneth Ducci, MD | |
Sub-Investigator: Francesco Liistro, MD | |
Sub-Investigator: Simone Grotti, MD |
Principal Investigator: | Leonardo Bolognese, MD, FESC | Ospedale San Donato |
Responsible Party: | Ospedale San Donato ( Cardiovascular Department USL 8(Leonardo Bolognese MD) ) |
Study ID Numbers: | Arezzo002, EUDRACT 2009-010295-23 |
Study First Received: | April 15, 2009 |
Last Updated: | April 16, 2009 |
ClinicalTrials.gov Identifier: | NCT00882739 History of Changes |
Health Authority: | Italy: Ethics Committee |
angiography percutaneous coronary intervention Platelet Aggregation Inhibitors Platelet Function Tests |
Necrosis Heart Diseases Clopidogrel Myocardial Ischemia Vascular Diseases |
Platelet Aggregation Inhibitors Ischemia Infarction Myocardial Infarction |
Heart Diseases Myocardial Ischemia Hematologic Agents Vascular Diseases Ischemia Pharmacologic Actions Necrosis |
Pathologic Processes Clopidogrel Therapeutic Uses Cardiovascular Diseases Platelet Aggregation Inhibitors Infarction Myocardial Infarction |